DISCOUNT OPTIONSSCHEIN - NOVO NORDISK ADR B | Market Closed - Deutsche Boerse AG 13:55:05 2024-05-17 EDT | ||
| 1.39 EUR | +1.46% |
|
| Current month | -4.79% | ||
| 1 month | -9.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 1.39 | +1.46% |
| 24-05-16 | 1.37 | +0.74% |
| 24-05-15 | 1.36 | -2.16% |
| 24-05-14 | 1.39 | 0.00% |
| 24-05-13 | 1.39 | -4.14% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 01:55 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD167G |
| ISIN | DE000VD167G5 |
| Date issued | 2024-03-13 |
| Strike | 170 $ |
| Maturity | 2025-06-20 (397 Days) |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.55 € |
|---|---|
| Lowest since issue | 1.34 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
